Global Hypoprothrombinemia Treatment Market, By Types (True Hypoprothrombinemia (Type I Deficiency), Dysprothrombinemia (Type II Deficiency), Treatment (Medication, Preventive Care and  Supplements), Product (Prothrombin Complex Concentrates (PCC) or Fresh Frozen Plasma (FFP) Drugs), Drugs (Phytomenadione, Menadoxime and Others), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics and Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029